Openbookopenbook
Equity
HRMY
+0.0 · +0.00%
USD · NASDAQ

Harmony Biosciences Holdings(HRMY) Stock Analysis | Healthcare

USD --+0.00%
Reward77High
Risk27Low
75%Data
Strong 19% profit margin · Revenue growing 30% YoY
Quality Compounder
Market Cap:2.22Bn
ⓘ
Reward Rating
77
High
Reward Assessment
75% data coverage
Top 10% of stocksView factors
ⓘ
Risk Rating
27
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HRMY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for HRMY, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $46.10.

What is Harmony Biosciences Holdings?

, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.

HRMY · Verdict

Strong reward · low risk

HRMY scores well on valuation and balance sheet with no major weaknesses flagged in the model.

Based on 88% data coverage

HRMY · Verdict

What’s working & what to watch

Strengths 5

  • Valuation100/100

    P/E 10.2× · PEG 0.36

  • Balance sheet99/100

    Interest covered 15.7×

  • Profitability95/100

    18% net margin · 20% ROE

  • Cash flow94/100

    40% free-cash-flow margin

  • Growth77/100

    Rev +25.6% CAGR · earnings -4.4%

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Harmony Biosciences Holdings?

, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.22B, and a P/E ratio of 12.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (77)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

KLRAMid Cap / 2.2B market cap
Kailera Therapeutics, Inc. Common Stock
Compare
AUPHMid Cap / 2.2B market cap
Aurinia Pharmaceuticals Inc
Compare
BHVNMid Cap / 2.2B market cap
Biohaven Ltd.
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap2.22B
P/E Ratio12.3463
Dividend YieldN/A
Beta0.913
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
350,640 shares
$1.9M
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.